Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
HP enters October with an interesting tension: the Street has grown meaningfully more constructive on Helmerich & Payne over the past few weeks, yet the stock has given back 11% over the past month to close at $39.61, sitting well below a cluster of freshly raised price targets.
The analyst picture is the clearest signal this week. Target upgrades have come in rapid succession from multiple directions. Susquehanna raised its target to $50 on October 5, UBS reinstated coverage with a Buy and a $49 target on October 2, and RBC Capital lifted to $49 on September 10. Citigroup moved its target to $48 from $36 on September 4. Even Morgan Stanley, which keeps an Underweight rating, nudged its target higher to $41. The consensus mean now sits at $45.13, implying more than 13% above the current price, and that average is being pulled up by bullish targets in the high $40s to $50. The outlier on the bearish side remains Morgan Stanley, whose $41 target is barely above the current price, reflecting concern about the cycle rather than outright collapse in fundamentals.
Factor scores add context to why the bulls have become louder. Helmerich & Payne ranks in the 100th percentile on 30-day EPS momentum and the 99th percentile on 90-day EPS momentum. The EPS surprise score ranks in the 98th percentile. Those are exceptional readings by any measure, suggesting estimates have been moving sharply higher in recent weeks and that the company has consistently beaten what analysts expected. Against that, the EV/EBIT factor score sits at just the 6th percentile, a reminder that the market is not yet paying a premium multiple for the drilling cycle recovery. The PE multiple has compressed roughly 24 points over the past 30 days, while EV/EBITDA has eased to 5.6x, both consistent with a stock that has retraced despite improving fundamentals.
Short positioning tells a quieter story, and is not the primary angle here. Short interest has held steady at around 7.3% of the free float, essentially flat on the week. Borrowing costs ticked up about 12% on the week but remain very low in absolute terms at 0.44%. Borrow availability is extremely loose, with roughly 19 times the currently shorted shares still available to lend. The ORTEX short score of 49.3 is right at the midpoint, reflecting no particular conviction from the short side. Options positioning is similarly unremarkable, with the put/call ratio at 0.84, almost exactly in line with its 20-day average and well within its recent range.
The insider register is worth flagging, even if it is not the dominant story. The 90-day net insider activity shows $5.9 million of net selling across multiple executives. The most notable single transaction was director Hans Helmerich, who sold roughly $4.1 million of stock at $43.90 per share on August 20, outside of any pre-arranged trading plan. The CLO and CAO also made open-market sales in August, equally without 10b5-1 plan protection. The EVP for Western Hemisphere Land has been selling regularly under a scheduled plan, which carries less signal. The discretionary sales by Helmerich and two other senior executives near $44 are worth noting given that the stock has since fallen back toward $39.
On the institutional side, BlackRock recently added 406,000 shares to lift its stake to 15.7% of shares outstanding. Invesco added 825,000 shares in its most recently reported period, a meaningful build. Neither holds an activist 13D position; all large holders are on the passive 13G register.
Earnings are scheduled for November 19. Recent post-result moves have been sharply positive: the stock gained 11.5% the day after the August print and followed that with a 29% move over the subsequent five days. The contrast between that reaction and the stock's current position about 11% below the post-earnings high sets up an interesting dynamic heading into the next quarter's close. The question heading into November is whether the combination of rising Street targets and strong earnings momentum can overcome whatever drove the discretionary insider selling above $43.
See the live data behind this article on ORTEX.
Open HP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
